Overview

A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.

Status:
Recruiting
Trial end date:
2022-03-04
Target enrollment:
Participant gender:
Summary
A clinical study to evaluate the long-term safety and tolerability of an investigational drug in people with schizophrenia. This study is accepting male and female participants between 18 years old -65 years old who have been diagnosed with schizophrenia. This study will be conducted in approximately 50 study centers worldwide. The study will last approximately 57 weeks.
Phase:
Phase 3
Details
Lead Sponsor:
Sunovion
Treatments:
Quetiapine Fumarate